PMID: 9451192Feb 6, 1998Paper

Recombinant human erythropoietin as a treatment for anemia of prematurity

The Journal of Perinatal & Neonatal Nursing
P Downey

Abstract

Anemia of prematurity (AOP) is an exaggerated form of the normal physiologic anemia of infancy. The primary pathophysiologic abnormality implicated in the development of AOP is inadequate production of erythropoietin, whose function is the regulation of red blood cell production. Recent studies into the safety and efficacy of recombinant human erythropoietin in infants with AOP have demonstrated consistently a rise in hematocrits and reticulocyte counts, fewer blood transfusions, reduced transfused volume of blood per kilogram body weight, and a decrease in bioavailable iron. Current dose recommendations are 200 U/kg subcutaneously or intravenously daily or every other day.

Citations

Jan 2, 2004·Indian Journal of Pediatrics·M Mahapatra, V P Choudhry
Apr 9, 2008·Current Medical Research and Opinion·Stefan KrivoshievUNKNOWN Epoetin Zeta Study Group
Jan 23, 2008·Current Medical Research and Opinion·Volker WizemannUNKNOWN Epoetin Zeta Study Group
Dec 12, 2000·Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners·M F McCourt, C M Griffin
Jul 30, 2002·Neonatal Network : NN·D C Salsbury

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.